A Ligand for Peroxisome Proliferator-Activated Receptor γ Inhibits Human Cholangiocarcinoma Cell Growth: Potential Molecular Targeting Strategy for Cholangioma
- 118 Downloads
Peroxisome proliferator-activated receptor γ (PPARγ) ligands have an antitumor effect. The aim of this study was to clarify whether PPARγ ligands could inhibit the growth of human cholangiocarcinoma cells. PPAR( expression in HuH-28 and HuCCT1 cells (intrahepatic bile duct carcinoma) was determined using the reverse transcription-polymerase chain reaction (RT-PCR). Expression of PPARγ mRNA was detected in both cell lines. Activation of PPARγ by troglitazone caused marked growth inhibition in a time- and dose-dependent manner. Troglitazone inhibited the growth of human cholangiocarcinoma cell lines by inducing apoptosis and by cell cycle regulation (G1 arrest), and this was associated with caspase 3 and caspase 9 activation. Thus, molecular targeting with troglitazone, a nuclear receptor ligand, may be a promising strategy for treating cholangiocarcinoma, although a delivery system needs to be established.
KeywordsPeroxisome proliferator-activated receptor γ Apoptosis Cell cycle
- 23.Takahashi T, Fujiwara Y, Higuchi K, et al. (2001) PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19:465–471Google Scholar